The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•17 April 2026•

1 min read

Virbac Reports Strong 7.7% Organic Growth in Q1 Despite Currency Headwinds

3D metallic 'PVH' text with 'CALVIN KLEIN' and 'TOMMY HILFIGER' names. Upward trend line, 'EARNINGS BEAT', 'REVENUE: +14%', and '2026 GUIDANCE' on an orange background.

Key Facts

1Q1 revenue reached €384m, representing a 7.7% increase at constant exchange rates and scope (CERS).

Virbac, a leading animal health company, reported robust financial results for the first quarter of 2026, with revenues reaching €384 million. The company achieved a solid 7.7% increase at constant exchange rates and scope (CERS), driven by balanced demand across both companion and farm animal segments. Notably, the 'Supercharge' priority platforms delivered exceptional growth of approximately 15%, highlighting strong operational execution. However, significant currency headwinds limited the actual reported revenue growth to 2.2% for the period. Despite these foreign exchange challenges, the underlying organic performance remains strong across global markets. This growth trajectory underscores the resilience of Virbac's core business model in a complex macroeconomic environment.